Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Oct;72(10):e31913.
doi: 10.1002/pbc.31913. Epub 2025 Jul 21.

Caregiving for Children With Acute Lymphoblastic Leukemia Receiving Home-Based Blinatumomab: Caregiver Experiences and Recommendations

Sue Zupanec  1   2 , Tessa Palmert  2 , Elham Hashemi  2 , Kyobin Hwang  2 , Terry Armstrong  3 , Katie Oranges  4 , Lauren Guidry  5 , Lindsay Jibb  1   2
Affiliations
Multicenter Study

Caregiving for Children With Acute Lymphoblastic Leukemia Receiving Home-Based Blinatumomab: Caregiver Experiences and Recommendations

Sue Zupanec et al. Pediatr Blood Cancer. 2025 Oct.

Abstract

Background: It is expected that blinatumomab will be increasingly incorporated into the care of children with B-lineage acute lymphoblastic leukemia (B-ALL) based on improved survival for subsets of patients and a favorable safety profile. Most of the 28-day continuous infusion can be administered in outpatient or home settings. Limited studies have described low rates of complications at home when appropriate safety plans are in place. However, home administration shifts the burden of monitoring and care to caregivers.

Procedure: Caregivers of children with B-ALL within 1 month of completing a first cycle of blinatumomab at home were recruited from three tertiary care centers and participated in virtual, audio-recorded, semi-structured interviews, with translation services available as required. Interviews were transcribed, coded independently in duplicate, and analyzed using thematic analysis. Identified caregiving context-specific barriers and facilitators were coded deductively.

Results: Participating caregivers (n = 21) described a time-bound confidence response where initial infusion anxiety was gradually replaced with caregiving self-assurance. Growing confidence co-occurred with improved caregiver wellness and child quality of life, characterized by resuming more usual family activities amid therapy. Barriers and facilitators to successful home-based blinatumomab included caregiver knowledge and skills, access to hospital-based support, and particular aspects of a family's social and material environment, and these underpinned recommendations for future caregivers.

Conclusions: Caregivers can confidently manage home-based continuous infusion blinatumomab with anticipatory guidance and support, and with attention paid to context-related modifiers to care. Caregiver insights should be reflected in the principles that become the basis of future pediatric B-cell ALL clinical trials and care.

Keywords: acute lymphoblastic leukemia; blinatumomab; caregiver; experiences; home‐based care; pediatric; qualitative.

PubMed Disclaimer

References

    1. K. W. Maloney, M. Devidas, and C. Wang, “Outcome in Children with Standard‐Risk B‐Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331,” Journal of Clinical Oncology 38 (2020): 602–612.
    1. P. A. Brown, L. Ji, and X. Xu, “Effect of Postreinduction Therapy Consolidation with Blinatumomab vs Chemotherapy on Disease‐Free Survival in Children, Adolescents, and Young Adults with First Relapse of B‐Cell Acute Lymphoblastic Leukemia,” JAMA 325 (2021): 833.
    1. A. C. Logan, “Lower Leukemia Burden Maximizes the Impact of Blinatumomab Therapy,” Cancer 129 (2023): 1316–1318.
    1. S. Gupta, R. E. Rau, and J. A. Kairalla, “Blinatumomab in Standard‐Risk B‐Cell Acute Lymphoblastic Leukemia in Children,” New England Journal of Medicine 392 (2024): 875–891.
    1. I. M. van der Sluis", R. S. Kotecha, and A. Attarbaschi, “Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia,” New England Journal of Medicine 388 (2023): 1572–1581.

Publication types

LinkOut - more resources